Revealing article on USA Govt Drug purchasing…. perhaps they are be looking at pharmacy with envy? Not strictly related to PEB… but interesting.
http://www.businessweek.com/articles...-drugs#r=hp-ls
Printable View
Revealing article on USA Govt Drug purchasing…. perhaps they are be looking at pharmacy with envy? Not strictly related to PEB… but interesting.
http://www.businessweek.com/articles...-drugs#r=hp-ls
I’ve only just got to the report, seems satisfyingly informative,
“We are aware of the need to inform shareholders about our business, and during the year, we focused on providing as much information as possible on the regulatory, reimbursement and adoption drivers for novel, medical devices in both New Zealand and the US.”
Given there’s been very little change in the top 100 holders one would presume the larger shareholders are routinely being ‘informed’ by Pacific Edge, are holding, and are satisfied.
“This will be a significant and on-going focus for the Company. We expect to see a number of research papers produced by local and international analysts to fill some of this knowledge gap during the coming year.”
I hope having now been teased with the prospect of these analyst reports that they are made public.
Prospectively one of these is very possibly the awaited Edison report. The market I suspect will respond positively to these reports even if they just serve to summarise the market potential and provide a DCF valuation.
Good to see the first NPN sales coming through which kicks off the 45% part of the growth curve now. We should anticipate a similar seven month lead in for CMS sales kick off.
From last year’s AGM we know that the market comprises;
50% Government (CMS, VA)
45% Private Insurance (NPN insurers, Kaiser Permanente, Intermountain etc)
5% Institutional OSHA
All on track for US$100M gross rev in five years and securing a humble 10% share of the market at that time.
My point?
-Up until now I had assumed that unless Cxbladder was covered by Insurance (CMS or Private) , it would not sell.
-PEB has not announced Insurance coverage (eg Kaiser, Cigna, Blue Shield etc). I have previously posted the BlueShield Policy and Cxbladder is mentioned but not yet approved - next review Nov
- What they have announced is deals with four National Provider Networks. These NPN's are not Insurers. They simply get a whole bunch of suppliers together (from Hospitals, doctors and the likes of PEB) , screw down the price . and offer the network to Insurers. They handle the claim and reimbursement yes , but do not approve the claim if outside of the Insurers Policy terms
- The Insurers and Vets review coverage (ie which tests are covered) from time to time and are influenced my CMS, which in turn is influenced by the likes of AHRT. This is why I was excited about the AHRQ enquiry into biomarkers for BC
- P13 of the Annual report (the blue box you are excited about) shows reimbursement from private Insurer from fedmed sale taking place May 14. (and while on this point, I'm encouraged by your renewed optimism but all it really demonstrates is that it took 7 months for Fedmed to sell a cxbladder test. Why?)
So that was my understanding on where PEB was at at. And because no one had responded to my posts with a different perspective of how it all might reasonably work, I assumed Miner was asking the question as well. What Insurance and who paid?
I was then told that Insurers usually pay claims until volume picks up, as posted. It makes no sense to me but it is what it is and explains the US sales Miner was questioning.
PEB has found support at 69c then 75c and more recently 77c. It's however still in a wedge pattern with lower highs at 93c, 88c and 82c. A bullish breakout will be confirmed if and only if these tops are broken.
Right now, even though the NBT was up over 2% overnight, PEB looks to be struggling to get through 80c (a new lower high?).
IMO: If and when it trades at 83c, it's a buy.
Alternatively, if and when it drops to test this year's bottom around 70c, it's a buy.
Meanwhile, I'm staying out.
Fundamentals are important sure, but it's technical analysis that confirms the impact that those fundamentals are having on the market price, and at the end of the day it's sp momentum that matters.
Then don't read them, Tsuba. I don't post for your entertainment.
Believe it or not, some people are more interested than you are in what a stock's charts are telling us. I like to research fundamentals, but time my trades based on technicals. What's your preferred approach?
BC
Yeah pretty negative Tsuba lets keep the channels open; i for one learn a lot re T/A etc from bobcat (thanks) and others; it expands my investment universe.
Off-topic, but in a similar vein, I heard David Shearer trying to blame the gummint over this diplomat immunity thingy on the radio this morning - he was meaning to say 'when the proverbial hits the fan', instead he stumbled on his words, as is usual for him, and came out with 'when the sh1t hits the proverbial'
Point taken. Sorry about that.